Microbot Medical Finalizes $13 Million Direct Offering
Microbot Medical Inc. (NASDAQ: MBOT), a pioneering company in the medical technology sector, has successfully concluded its registered direct offering. This strategic move reflects the company’s commitment to advancing its innovative technologies designed to enhance patient care across the globe.
Details of the Offering
The offering involved the sale of 6,103,289 shares of common stock at a significant price of $2.13 per share. Alongside this, Microbot also conducted a private placement for unregistered short-term series I preferred investment options, allowing investors the opportunity to purchase an additional 12,206,578 shares under similar terms.
Exclusive Placement Agent
H.C. Wainwright & Co. has taken a prominent role as the exclusive placement agent for these offerings. Their expertise in the financial sector played a crucial part in facilitating a smooth transaction.
Proceeds and Future Endeavors
This financial maneuver has yielded approximately $13 million in gross proceeds before necessary fees and expenses are deducted. Microbot Medical plans to utilize these funds judiciously to further develop their LIBERTY Robotic System. This advanced robotic system is designed to revolutionize the endovascular procedures, contributing significantly to patient safety and efficiency.
Advancing Technological Applications
In addition to enhancing the capabilities of the LIBERTY system, the proceeds will support initiatives related to regulatory activities, as well as research and development for new applications from the company’s extensive intellectual property portfolio. Such investments indicate the company's robust strategy in maintaining its competitive edge in the healthcare technology space.
Regulatory Compliance and Offer Details
Microbot Medical's offering was executed under an existing shelf registration statement, granting them the flexibility to utilize market conditions to secure funding. While shares were offered under this registration, the private placement is exempt from such registration requirements, showcasing Microbot's compliance with the relevant regulations.
Company Overview
As a clinical stage medical technology company, Microbot Medical is dedicated to innovating solutions that improve healthcare delivery. They have developed the first single-use, fully disposable endovascular robotic system, which aims to break down barriers traditionally associated with advanced robotic technologies in the medical field.
Investor Relations and Further Information
For those interested in understanding more about Microbot Medical's initiatives and ongoing projects, comprehensive details can be found on their official website. Their dedication to transparency and communication ensures that investors and stakeholders keep informed on the company’s progress and future aspirations.
Contact Details
For any inquiries or further information, Microbot Medical welcomes contact via their investor relations email: IR@microbotmedical.com.
Frequently Asked Questions
What is the amount raised in Microbot Medical's recent offering?
The recent offering raised approximately $13 million, which will support various company initiatives.
Who acted as the placement agent for this offering?
H.C. Wainwright & Co. served as the exclusive placement agent for the offerings.
What will the proceeds be used for?
The funds will be directed toward the development of the LIBERTY Robotic System and various corporate needs.
What is the significance of the LIBERTY Robotic System?
The LIBERTY Robotic System is designed to enhance endovascular procedures and improve patient care substantially.
How can I learn more about Microbot Medical?
For more information, you can visit their official website or contact their investor relations directly at IR@microbotmedical.com.
